Andrew Mazar

Dr. Andrew P. Mazar has served as Actuate Therapeutics' Chief Operating Officer since June 2022, after serving as an independent consultant to the company from January to June 2022. A translational oncology researcher and entrepreneur with over 30 years of experience spanning academia and industry, he was previously Co-Founder, Chief Scientific Officer and a director of Monopar Therapeutics, Inc. from 2016 to 2022, and is a founder and managing member of Tactic Pharma, LLC, where he co-invented WTX-101/ALXN1840 (acquired by Alexion Pharmaceuticals for more than $800 million in 2018). He was previously a Professor of Pharmacology and Director of the Center for Developmental Therapeutics at Northwestern University's Feinberg School of Medicine, and Chief Scientific Officer at Attenuon, LLC. He is a co-author of roughly 150 peer-reviewed publications and a co-inventor on more than 100 patents. Dr. Mazar earned a B.S. in Chemistry from the University of Wisconsin-Parkside and a Ph.D. in Biochemistry from the University of Illinois College of Medicine, Chicago.

Fixed Compensation

Performance Compensation

You're subscribed.

Thanks for signing up.